New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical "game changer
US biotech EVOQ Therapeutics has lined up another partner for its NanoDisc immunotherapy technology, with Gilead Sciences buying into the platform in a deal valued at up to $658.5 million.<
